GC012F (AZD0120)

A Phase 1 Study of GC012F (AZD0120), a Chimeric Antigen Receptor T-cell (CAR T) Therapy Targeting CD19 and B-cell Maturation Antigen (BCMA) in Early-Line Treatment in Subjects With Multiple Myeloma

Arms / Cohorts

Experimental:GC012F (AZD0120): Newly Diagnosed Patients

Accepting patients

Experimental:GC012F (AZD0120): Early Relapsed or Primary Refractory Patients

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.